Overview

Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients

Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
'ThRIL' aims to explore the feasibility, safety and efficacy of TR002, a regulatory cell therapy, as adjunct immunosuppressive treatment in the context of liver transplantation
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborator:
King's College London